These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 31173106

  • 1. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Neuro Oncol; 2019 Nov 04; 21(11):1401-1411. PubMed ID: 31173106
    [Abstract] [Full Text] [Related]

  • 2. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.
    Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Clin Cancer Res; 2019 Jun 01; 25(11):3374-3383. PubMed ID: 30796030
    [Abstract] [Full Text] [Related]

  • 3. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.
    Clin Cancer Res; 2016 May 01; 22(9):2250-60. PubMed ID: 26733612
    [Abstract] [Full Text] [Related]

  • 4. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.
    Mol Cancer Ther; 2011 Dec 01; 10(12):2426-36. PubMed ID: 21998291
    [Abstract] [Full Text] [Related]

  • 5. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
    Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.
    PLoS One; 2013 Dec 01; 8(6):e67258. PubMed ID: 23826249
    [Abstract] [Full Text] [Related]

  • 6. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW.
    Breast Cancer Res Treat; 2012 Dec 01; 136(3):673-82. PubMed ID: 23085766
    [Abstract] [Full Text] [Related]

  • 7. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.
    Breast Cancer Res; 2014 Aug 08; 16(4):406. PubMed ID: 25103565
    [Abstract] [Full Text] [Related]

  • 8. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD.
    Am J Obstet Gynecol; 2013 Nov 08; 209(5):465.e1-9. PubMed ID: 23891627
    [Abstract] [Full Text] [Related]

  • 9. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    Neoplasia; 2014 Jan 08; 16(1):43-72. PubMed ID: 24563619
    [Abstract] [Full Text] [Related]

  • 10. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
    Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, Lee LB, Risom T, Gross S, Liederer BM, Koeppen H, Skelton NJ, Wallin JJ, Belvin M, Punnoose E, Friedman LS, Lin K.
    Clin Cancer Res; 2013 Apr 01; 19(7):1760-72. PubMed ID: 23287563
    [Abstract] [Full Text] [Related]

  • 11. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.
    Breast Cancer Res; 2011 Mar 01; 13(2):R21. PubMed ID: 21362200
    [Abstract] [Full Text] [Related]

  • 12. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J.
    Clin Cancer Res; 2013 Oct 01; 19(19):5413-22. PubMed ID: 23888070
    [Abstract] [Full Text] [Related]

  • 13. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I.
    J Hematol Oncol; 2020 Feb 22; 13(1):13. PubMed ID: 32087759
    [Abstract] [Full Text] [Related]

  • 14. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
    Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP.
    Clin Cancer Res; 2019 Jul 15; 25(14):4375-4387. PubMed ID: 30975663
    [Abstract] [Full Text] [Related]

  • 15. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
    Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K.
    Oncotarget; 2016 Nov 29; 7(48):79526-79543. PubMed ID: 27765909
    [Abstract] [Full Text] [Related]

  • 16. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S, Tang Y, Yan M, Jiang W.
    Invest New Drugs; 2018 Oct 29; 36(5):763-772. PubMed ID: 29504069
    [Abstract] [Full Text] [Related]

  • 17. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL, Kim HP, Cho YW, Min DW, Cheon SK, Lim YJ, Song SH, Kim SJ, Han SW, Park KJ, Kim TY.
    Int J Cancer; 2019 Jan 15; 144(2):389-401. PubMed ID: 29978469
    [Abstract] [Full Text] [Related]

  • 18. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ, Brauer H, Horn S, Yigit G, Haider MT, Pogenberg V, Schumacher U, Pantel K, Jücker M.
    Cell Signal; 2024 Sep 15; 121():111270. PubMed ID: 38909932
    [Abstract] [Full Text] [Related]

  • 19. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.
    Clin Cancer Res; 2013 Jul 15; 19(14):3808-19. PubMed ID: 23640975
    [Abstract] [Full Text] [Related]

  • 20. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.
    Breast Cancer Res; 2014 Jan 27; 16(1):R13. PubMed ID: 24467828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.